Nasdaq

Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Positive Cancers

CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...
Business Wire

Transgene to Present Phase 1b/2 Trial Results of TG4001 in Combination with avelumab in Advanced HPV-Positive Cancers at ESMO IO 2020

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will present the Phase 1b/2 ...
Business Insider

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

Combination of PDS0101 and KEYTRUDA ® appears to lead to changes towards a TH1 predominant cytokine profile reported to be associated with improved killer T cell activity Lowered CD8 T cells in ...
Business Wire

Repertoire Immune Medicines Announces First Patient Dosed in Phase 1 Clinical Study of RPTR-168 (PRIME IL-12) for Relapsed or Refractory HPV-16-Positive Tumors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repertoire Immune Medicines announced today that the first patient has been dosed in the company’s Phase 1 study of RPTR-168 (PRIME IL-12) in patients with select ...
Nasdaq

Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action

CAMBRIDGE, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...
Seeking Alpha

PDS Biotech reports encouraging survival data for HPV 16+ cancer therapy

PDS Biotech (NASDAQ:PDSB) reported encouraging updated survival data from a Phase 2 study of triple combination of the drug candidates PDS0101, PDS0301 and an investigational checkpoint inhibitor, or ...
CNN

Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Association of ...

CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...
Fox2Now St. Louis

Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer

Nykode to further elaborate on trial design and development strategy at upcoming capital markets day in New York on September 20. OSLO, Norway, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ...
Business Insider

INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from ...
JSTOR Daily

Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer

Background. Data on the relative carcinogenic potential of human papillomavirus (HPV) types among women infected with human immunodeficiency virus (HIV) (WHIV) are needed to inform prevention programs ...
Seeking Alpha

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

PRINCETON, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted ...